Is Liver Resection in Metastases of Exocrine Pancreatic Carcinoma Justified?
DOI:
https://doi.org/10.6092/1590-8577/3390Keywords:
Adenocarcinoma, Hepatectomy, Neoplasm Metastasis, Pancreatic Neoplasms, PancreaticoduodenectomyAbstract
No abstract available.
Image: College of Physicians and Surgeons, Columbia University. New York, NY, USA
Downloads
References
Singh A, Singh T, Chaudhary A. Synchronous resection of solitary liver metastases with pancreaticoduodenectomy. JOP. J Pancreas (Online) 2010; 11:434-8. [PMID 20818110]
Gleisner AL, Assumpcao L, Cameron JL, Wolfgang CL, Choti MA, Herman JM, et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer 2007; 110:2484-92. [PMID 17941009]
Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297:267-77. [PMID 17227978]
Neoptolemos J, Büchler M, Stocken DD, Ghaneh P, Smith D, C. Bassi C, et al. A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol 2009; 27(18 Suppl):Abstract LBA4505.
Breysacher G, Kaatz O, Lemarignier C, Chiappa P, Roncalez D, Denis B; et al. Safety and clinical effectiveness of FOLFIRINOX in metastatic pancreas cancer (MPC) after first-line chemotherapy. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 269.
